Dronabinol is synthetic tetrahydrocannabinol ('THC'), which obtained FDA approval in 1985 for the treatment of HIV/AIDs-induced anorexia and chemotherapy-induced nausea and vomiting in patients who have failed to respond to conventional antiemetics. Dronabinol has also been used off-label for the treatment of OSA. This activity will provide an overview of the pharmacology of dronabinol, its indications and usage, adverse effects, contraindications, and other pertinent information.

**Objectives:**
- Describe the indications for dronabinol.
- Describe the mechanism of action for dronabinol.
- Review the potential toxicity of dronabinol.
- Identify potential drug interactions with dronabinol.